"KKR Financial Holdings (KFN) is a leading alternative asset manager; led by its founders, Henry Kravis and George Roberts, KKR specializes in large, complex buyouts," notes Mark Skousen.

The editor of The Hedge Fund Trader explains, "The company's edge is industry-leading private equity experience, in-depth industry knowledge, sophisticated processes for growing and improving businesses and an almost unbeatable information network.

"KKR has a history of landmark achievements in private equity, including the first leverage buyout above the $1-billion mark.

"Is Bristol-Myers Squibb (NYSE: BMY) ripe for a buyout?," asks growth expert Karim Rahemtulla. Here's an assessment from the investment director of Xcelerated Profits Report.

"I've predicted over the last several months that the larger pharmaceutical companies would be on the prowl for possible acquisitions.

"As it stands now, we probably haven't seen the last of such offers - and thanks to the previous two large mergers recently announced Merck acquiring Schering Plough and Pfizer buying Wyeth, many analysts are now speculating that Bristol-Myers Squibb could be next.